SecBot SecBot
8-K ·Filed May 11, 2026

AGEN

AGENUS INC
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago SEC0001193125-26-215838
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The removal of SEC investigation risk and class action dismissal, combined with a strengthened balance sheet from the Zydus deal and the start of Phase 3 enrollment, represent a material de-risking of the BOT+BAL program. Monitor for regulatory submission updates in the U.S. and EU, and for the next quarterly cash burn rate to gauge whether the $50M annualized operating expense target is being met.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.26
T+0 close · May 11, 2026 · via day close
Latest settled
+138.65%
T+60 · $7.78
Vs SPY
+134.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $3.26entry
  2. T+1 · 6mo ago +5.52%α +5.66% · $3.44
  3. T+5 · 6mo ago −3.07%α −2.98% · $3.16
  4. T+20 · 5mo ago −4.60%α −4.30% · $3.11
  5. T+60 · 3mo ago +138.65%α +134.26% · $7.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Agenus reported Q1 2026 total revenue of $33.7M (up from $24.1M YoY) and net income of $39.2M vs a net loss of $26.4M in Q1 2025, driven by $29.1M in non-cash royalty revenue and $4.6M in pre-commercial product revenue from BOT+BAL early access programs. The company ended the quarter with $35.0M in cash (up from $3.0M at year-end 2025) after closing the Zydus collaboration, which delivered $91M in upfront capital. The SEC investigation concluded with no enforcement action, and the related securities class action was dismissed, removing two key legal overhangs.

Key Financial Metrics

Revenue
$33.7M
est $129.5M · -74.0% · +39.8% YoY

Key Facts

  • Total revenue $33.7M in Q1 2026 vs $24.1M in Q1 2025 (up 39.8% YoY)
  • Net income of $39.2M vs net loss of $26.4M in Q1 2025
  • Operating income of $15.1M vs operating loss of $(13.3)M in Q1 2025
  • Cash and equivalents $35.0M at March 31, 2026 vs $3.0M at December 31, 2025
  • Zydus collaboration closed in January 2026 with $91M upfront capital
  • SEC investigation concluded May 4, 2026 with no enforcement action recommended
  • Securities class action dismissed in its entirety by U.S. District Court on March 24, 2026
  • Phase 3 BATTMAN trial commenced patient enrollment in April 2026
  • Pre-commercial product revenue of $4.6M from BOT+BAL early access programs
  • Subsequent to quarter-end, received $11.7M in net proceeds from ATM equity sales

Financial Impact

Revenue increased 39.8% YoY to $33.7M; net income swung positive by $65.6M vs prior year loss; cash position improved by $32.0M from year-end 2025

revenuenet incomecash positionoperating income

Risk Factors

  • Lead plaintiff has filed a Notice of Appeal on the class action dismissal
  • Cash payments of $51.8M in Q1 included one-time Zydus closing costs; recurring burn rate still to be confirmed
  • BOT+BAL remains unapproved; regulatory outcomes are binary and years away
  • Dilution risk from ATM program, $11.7M in net proceeds raised post-quarter-end

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-215838
Document: agen-20260511.htm0001193125-26-215838
Document: 0001193125-26-215838-index-headers.html0001193125-26-215838
Document: 0001193125-26-215838-index.html0001193125-26-215838
Document: 0001193125-26-215838.txt0001193125-26-215838
8-K Data (Synthetic)0001193125-26-215838

Track record

12 reports on AGEN

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +25.70% at T+60 after the Dec 4, 2025 report. 3 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
  3. Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
  4. Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
  5. Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
  6. Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
  7. Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
  8. Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
  9. Jul 13, 202618w ago 8-K Bearish 6/10 Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
  10. May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026